Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.

Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A.

J Exp Med. 2012 Apr 9;209(4):679-96. doi: 10.1084/jem.20111512. Epub 2012 Mar 19.

2.

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.

Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A.

Nat Med. 2016 Nov;22(11):1321-1329. doi: 10.1038/nm.4213. Epub 2016 Oct 24.

3.

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.

Kang J, Sergio CM, Sutherland RL, Musgrove EA.

BMC Cancer. 2014 Jan 20;14:32. doi: 10.1186/1471-2407-14-32.

4.

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. Review.

5.

c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.

Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P.

Mol Cancer. 2011 Sep 7;10:110. doi: 10.1186/1476-4598-10-110.

6.

Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.

Collins DC, Cocchiglia S, Tibbitts P, Solon G, Bane FT, McBryan J, Treumann A, Eustace A, Hennessy B, Hill AD, Young LS.

Oncogene. 2015 Jan 22;34(4):525-30. doi: 10.1038/onc.2013.586. Epub 2014 Jan 27.

PMID:
24469058
7.

Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

Reynolds C, Roderick JE, LaBelle JL, Bird G, Mathieu R, Bodaar K, Colon D, Pyati U, Stevenson KE, Qi J, Harris M, Silverman LB, Sallan SE, Bradner JE, Neuberg DS, Look AT, Walensky LD, Kelliher MA, Gutierrez A.

Leukemia. 2014 Sep;28(9):1819-27. doi: 10.1038/leu.2014.78. Epub 2014 Feb 20.

8.

CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.

Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S.

Cancer Res. 2012 Aug 15;72(16):4225-37. doi: 10.1158/0008-5472.CAN-12-1118. Epub 2012 Jun 12.

9.

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H.

J Clin Invest. 2012 Apr;122(4):1541-52. doi: 10.1172/JCI58765. Epub 2012 Mar 26. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702.

10.

Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.

Tarasewicz E, Rivas L, Hamdan R, Dokic D, Parimi V, Bernabe BP, Thomas A, Shea LD, Jeruss JS.

Cell Cycle. 2014;13(20):3191-201. doi: 10.4161/15384101.2014.950126.

11.

Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

Gründker C, Föst C, Fister S, Nolte N, Günthert AR, Emons G.

Breast Cancer Res. 2010;12(4):R49. doi: 10.1186/bcr2606. Epub 2010 Jul 14.

12.
13.

Therapeutic options for triple-negative breast cancers with defective homologous recombination.

Jaspers JE, Rottenberg S, Jonkers J.

Biochim Biophys Acta. 2009 Dec;1796(2):266-80. doi: 10.1016/j.bbcan.2009.07.001. Epub 2009 Jul 17. Review.

PMID:
19616605
14.

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.

Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K.

Mol Cancer Ther. 2016 Apr;15(4):593-607. doi: 10.1158/1535-7163.MCT-15-0519. Epub 2016 Jan 29.

15.

PUMA and BIM are required for oncogene inactivation-induced apoptosis.

Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH.

Sci Signal. 2013 Mar 26;6(268):ra20. doi: 10.1126/scisignal.2003483.

16.

HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.

Le XF, Pruefer F, Bast RC Jr.

Cell Cycle. 2005 Jan;4(1):87-95. Epub 2005 Jan 10. Review.

PMID:
15611642
17.
18.

Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.

Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H, Rochefort H.

Oncogene. 1991 Mar;6(3):431-7.

PMID:
1707153
19.

Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.

Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.

Eur J Cancer. 2011 Aug;47(12):1779-88. doi: 10.1016/j.ejca.2011.06.017. Epub 2011 Jul 7.

PMID:
21741827
20.

Potential therapeutic target for triple-negative breast cancer.

Gilbert JA.

Lancet Oncol. 2012 Aug;13(8):e330. No abstract available.

PMID:
23024992

Supplemental Content

Support Center